DIABETES MELLITUS target enzymes and drugs.
Diabetes Mellitus: Target Enzymes and Drugs highlights the importance of different targets in lead drug discovery and the importance of the synthesis of lead analogues.The book discusses the role of target enzymes, receptors, and related drugs in diabetes mellitus that are necessary for research on...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[S.l.] :
Academic Press,
2025.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- 5.6.4 Synthesis of tofoglifozin via construction of dihydroisobenzofuran by intramolecular [4+2] cycloaddition
- 5.6.5 Diarylmethanes, key building blocks for SGLT2 inhibitors
- 5.6.6 Thioglucoside analogues of gliflozin as potent new gliflozin drugs
- 5.6.7 Fukuyama coupling reaction for SGLT2 inhibitors synthesis
- 5.7 Conclusion
- Acknowledgment of funding
- List of abbreviations
- References
- 6 Insulin agonist in diabetes mellitus
- 6.1 Introduction
- 6.2 Mechanism of human insulin
- 6.2.1 Origin and function human insulin
- 6.2.2 Structure of human insulin
- 6.3 Insulin for management of diabetes
- 6.3.1 Insulin in injectable form and site
- 6.3.2 Characteristics of insulin
- 6.3.3 Insulin strength
- 6.4 Types of insulin
- 6.4.1 Agonists
- 6.4.2 Insulin agonist
- 6.4.3 Novel insulin agonist
- 6.4.4 Insulin-like peptide 5
- 6.4.5 Vasoactive intestinal peptide receptor 2
- 6.4.6 MK-1462: glucagon-like peptide-1 and glucagon receptor dual agonist
- 6.5 Adverse effect of insulin
- 6.5.1 Common adverse effects of insulin
- 6.5.2 Adverse effects comparison in insulin types
- 6.5.3 Rare adverse effects of insulin
- 6.6 Conclusion
- Acknowledgment of funding
- Abbreviations
- References
- 7 Glucagon-like-peptide-1 receptor agonists in diabetes mellitus
- 7.1 Introduction
- 7.2 Pharmacological actions of glucagon-like-peptide-1 receptor agonists
- 7.2.1 Mode of action of glucagon-like-peptide-1 receptor agonists
- 7.3 FDA-approved GLP 1 receptor agonists for the management of diabetes
- 7.3.1 Exenatide
- 7.3.1.1 Mechanism of action
- 7.3.1.2 Pharmacokinetic properties
- 7.3.1.3 Indications and dosage recommendations
- 7.3.2 Liraglutide
- 7.3.2.1 Mechanism of action
- 7.3.2.2 Indication and dosage recommendations
- 7.3.2.3 Dosage recommendations for special populations
- 7.3.3 Dulaglutide.
- 7.3.3.1 Mechanism of action
- 7.3.3.2 Indications and dosage recommendations
- 7.3.4 Lixisenatide
- 7.3.4.1 Mechanism of action
- 7.3.4.2 Indication and dosage recommendations
- 7.3.5 Albiglutide
- 7.3.5.1 Mechanism of action
- 7.3.5.2 Pharmacokinetic properties
- 7.3.5.3 Indications and dosage recommendations
- 7.3.6 Semaglutide
- 7.3.6.1 Mechanism of action
- 7.3.6.2 Pharmacokinetic properties
- 7.3.6.3 Indications and dosage recommendations
- 7.4 Adverse reactions of glucagon-like-peptide-1 receptor agonists
- 7.4.1 Contraindications of glucagon-like-peptide-1 receptor agonists
- 7.5 Other incretin-based drugs
- 7.5.1 Tirzapetide
- 7.5.2 Retatrutide
- 7.5.3 Orforglipron
- 7.5.4 Taspoglutide
- 7.6 Conclusion
- References
- 8 Amylin in diabetes mellitus
- 8.1 Introduction
- 8.2 Amylin mechanism of action
- 8.2.1 Link between amylin and diabetes mellitus
- 8.2.2 Amyloid formation
- 8.2.3 Cosecretion of amylin with insulin from pancreatic beta cells
- 8.2.4 Role of amylin in satiety regulation
- 8.3 Amylin agonists for management of diabetes
- 8.3.1 Amylin analogs and diabetic management
- 8.3.1.1 Pramlintide
- 8.3.2 Amylin agonist mechanism of action
- 8.4 Adverse effects of amylin agonists
- 8.4.1 Clinical adverse effects of amylin agonists
- 8.5 Dosing and dosage adjustments for amylin agonists
- 8.5.1 Dosing of amylin in special category people
- 8.5.1.1 Elderly population
- 8.5.1.2 Pediatric population
- 8.5.2 Dosage adjustment in hepatic and renal impaired patients
- 8.5.2.1 Renal impairment
- 8.5.2.2 Hepatic impairment
- 8.5.3 Monitoring amylin levels in diabetes patients
- 8.5.4 Clinical assessments
- 8.5.5 Adverse effects monitoring
- 8.6 Amylin research in diabetes and future directions
- 8.7 Conclusion
- References
- 9 Miscellaneous drug combinations in diabetes mellitus
- 9.1 Introduction.